Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NYMX Stock Price Chart Interactive Chart >
NYMX Price/Volume Stats
|Current price||$0.29||52-week high||$2.10|
|Prev. close||$0.30||52-week low||$0.19|
|Day high||$0.30||Avg. volume||229,363|
|50-day MA||$0.35||Dividend yield||N/A|
|200-day MA||$0.72||Market Cap||25.91M|
Nymox Pharmaceutical Corporation (NYMX) Company Bio
Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.
Most Popular Stories View All
NYMX Latest News Stream
|Loading, please wait...|
NYMX Latest Social Stream
View Full NYMX Social Stream
Latest NYMX News From Around the Web
Below are the latest news stories about NYMOX PHARMACEUTICAL CORP that investors may wish to consider to help them evaluate NYMX as an investment opportunity.
From what we can see, insiders were net buyers in Nymox Pharmaceutical Corporation's ( NASDAQ:NYMX ) during the past 12...
IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with and has met with the FDA during the past few months. The agency has provided very helpful feedback to the Company. FDA has specified what additional information is required in resubmission of the NDA; and the Company is in the process of preparing the requested documentation for the resubmission of re
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities. Nymox wishes to assure our shareholders that business plans are continuing to be developed and are on track. The Company will provide regular and further specific details when there is upcoming material information available to share. In the meantime, ongoing initiatives are continuing and are being
IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2). The Nasdaq letter states that the Company will be afforded 180 calendar days to regain compliance with the minimum bid price requirement. In order to regain compliance, the Company must have a closing bid price of $1.00 or more for
NYMX Price Returns
Continue Researching NYMXHere are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:
Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch